PAM
TCRX icon

Panagora Asset Management’s TScan Therapeutics TCRX Stock Holding History

Panagora Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.1K Buy
28,797
+3,541
+14% +$3.78K ﹤0.01% 1155
2025
Q4 		$25.3K Buy
+25,256
New +$36.6K ﹤0.01% 1176

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Panagora Asset Management's TCRX Position: Q1 2026 in Review

Panagora Asset Management increased its TScan Therapeutics (TCRX) stake by 14% in Q1 2026, buying an estimated $3.78K and bringing the position to 28,797 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1155.

Panagora Asset Management first reported a position in TCRX in Q4 2025 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Panagora Asset Management held 28,797 shares of TScan Therapeutics worth $29.1K as of Q1 2026.
  • Panagora Asset Management bought 3,541 TScan Therapeutics shares in Q1 2026, an estimated $3.78K.
  • TScan Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q1 2026, its #1155 holding.
  • Panagora Asset Management first reported a position in TScan Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.